| Literature DB >> 30108945 |
David Cousin1, Marc G Hummersone1, Tracey D Bradshaw2, Jihong Zhang2, Christopher J Moody3, Magdalena B Foreiter3, Helen S Summers3, William Lewis3, Richard T Wheelhouse4, Malcolm F G Stevens2.
Abstract
A series of 3-(benzyl-substituted)-imidazo[5,1-d]-1,2,3,5-tetrazines (13) and related derivatives with 3-heteromethyl groups has been synthesised and screened for growth-inhibitory activity in vitro against two pairs of glioma cell lines with temozolomide-sensitive and -resistant phenotypes dependent on the absence/presence of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). In general the compounds had low inhibitory activity with GI50 values >50 μM against both sets of cell lines. Two silicon-containing derivatives, the TMS-methylimidazotetrazine (9) and the SEM-analogue (10), showed interesting differences: compound (9) had a profile very similar to that of temozolomide with the MGMT+ cell lines being 5 to 10-fold more resistant than MGMT- isogenic partners; the SEM-substituted compound (10) showed potency across all cell lines irrespective of their MGMT status.Entities:
Year: 2018 PMID: 30108945 PMCID: PMC6072467 DOI: 10.1039/c7md00554g
Source DB: PubMed Journal: Medchemcomm ISSN: 2040-2503 Impact factor: 3.597